Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani was named a delegate to the Psychedelic Medicine Coalition’s annual federal policy summit held May 14, 2026 at the National Press Club in Washington, D.C.
The summit gathered U.S. federal officials, legislators, researchers, clinicians and biopharma leaders to discuss psychedelic medicine policy. Clearmind is advancing a non-hallucinogenic psychedelic candidate in Phase IIa clinical trials at Johns Hopkins, Yale, and other leading sites.
Clearmind Medicine (Nasdaq: CMND) reported an important milestone in its FDA-approved Phase I/IIa trial of CMND-100 (MEAI) for moderate to severe alcohol use disorder, with 20 participants now treated across all cohorts.
The fourth cohort uses a 160 mg dose, initiated after a positive DSMB recommendation and successful completion of three cohorts (18 participants) that met the primary safety endpoint with no serious adverse events. The multinational, multicenter study assesses safety, tolerability, pharmacokinetics, and preliminary efficacy at leading institutions including Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: New Insights from the CMND-100 Psychedelic Clinical Trial,” on June 10, 2026, 4:00–5:00 PM IDT.
The event will review latest Phase I/IIa CMND-100 data in Alcohol Use Disorder, featuring investigators from Yale and Johns Hopkins, and include corporate updates and a live Q&A.
Clearmind Medicine (Nasdaq: CMND) filed a European patent application on May 5, 2026 for novel, non‑hallucinogenic neuroplastogen-derived compounds targeting PTSD and other mental health disorders. The filing is part of Clearmind’s exclusive worldwide license from Yissum, granting global development, manufacturing, and commercialization rights.
The company said the filing strengthens its intellectual property position in Europe. The announcement cites a 2025 PTSD market valuation of USD 18.5 billion and a projected USD 30.2 billion by 2035. The release also references an April 18, 2026 executive order directing faster federal review of psychedelic-based therapies.
Clearmind Medicine (NASDAQ: CMND) said it is evaluating its lead candidate CMND-100 (MEAI) for potential FDA Breakthrough Therapy Designation based on positive results from its ongoing FDA‑approved Phase I/IIa Alcohol Use Disorder trial. The company has not yet submitted a BTD request and the FDA has not granted designation.
The announcement cites recent policy changes that may accelerate FDA review of certain psychedelic and neuroplastogen therapies.
Clearmind Medicine (Nasdaq: CMND) welcomed President Trump’s April 18, 2026 Executive Order prioritizing FDA review and expanded access pathways for certain psychedelic breakthrough therapies.
The company highlighted its non‑hallucinogenic neuroplastogen MEAI (CMND-100), its naming in H.R. 7091 (Feb 2026), and ongoing FDA‑approved Phase I/IIa trials at Yale and Johns Hopkins.
Clearmind Medicine (Nasdaq: CMND) announced that CMND-100, its non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder, met the primary safety and tolerability endpoint in the FDA-approved Phase I/IIa dose-escalation trial on April 20, 2026.
Data from the third cohort showed a high safety profile, favorable overall tolerability, and no serious adverse events, including at the highest dose tested, supporting continued clinical advancement.
Clearmind Medicine (Nasdaq: CMND) said an independent Data and Safety Monitoring Board gave a positive recommendation to continue its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder after the third cohort.
The DSMB found CMND-100 well tolerated with no serious adverse events, and the company will advance to a fourth cohort testing an increased 160mg dose.
Clearmind Medicine (Nasdaq: CMND) reported that its oral candidate CMND-100 met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa dose-escalation trial for Alcohol Use Disorder on April 14, 2026. The third cohort showed a high safety profile with no serious adverse events and continued favorable tolerability, including at the highest dose tested to date. The multinational, multicenter study assessed safety, tolerability, pharmacokinetics, and preliminary efficacy; meeting the primary endpoint supports continued clinical advancement of CMND-100 as a potential non-hallucinogenic AUD treatment.
Clearmind Medicine (Nasdaq: CMND) announced on March 30, 2026 the successful completion of treatment and follow-up for 18 participants in its FDA‑approved Phase I/IIa trial of CMND-100, a non‑hallucinogenic MEAI‑based oral candidate for Alcohol Use Disorder.
The company also treated four additional participants at its Tel Aviv site, and the multinational trial includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.